AEON Biopharma (AEON) has shared an update.
AEON has halted its Phase 2 study and related open label extension study on ABP-450 for migraine treatment after the trials failed to meet primary endpoints, though some secondary goals were achieved. Patients will continue to be monitored for safety. This decision will help AEON save cash as it considers future strategic directions.
Find detailed analytics on AEON stock on TipRanks’ Stock Analysis page.
